Abbvie Inc

NYSE:ABBV   4:00:00 PM EDT
+0.71 (+0.45%)
7:47:32 PM EDT: $159.16 +0.91 (+0.58%)
Products, Regulatory

Abbvie's Rinvoq Meets Primary And All Ranked Secondary Endpoints In Ulcerative Colitis study

Published: 12/09/2020 13:55 GMT
Abbvie Inc (ABBV) - Upadacitinib (rinvoq™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis.
Abbvie - Significantly More Upadacitinib-treated Patients Achieved Clinical Remission at Week 8 Versus Placebo.
Abbvie Inc - Safety Results in Study Were Consistent With Known Profile of Upadacitinib, With No New Safety Risks Observed.